Ngundi Miriam M, Meade Bruce D, Lin Tsai-Lien, Tang Wei-Jen, Burns Drusilla L
Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.
Clin Vaccine Immunol. 2010 Jun;17(6):895-903. doi: 10.1128/CVI.00513-09. Epub 2010 Apr 7.
Different types of anthrax toxin neutralization assays have been utilized to measure the antibody levels elicited by anthrax vaccines in both nonclinical and clinical studies. In the present study, we sought to determine whether three commonly used toxin neutralization assays-J774A.1 cell-, RAW 264.7 cell-, and CHO cell-based assays-yield comparable estimates of neutralization activities for sera obtained after vaccination with anthrax vaccines composed of recombinant protective antigen (rPA). In order to compare the assays, sera were assayed alongside a common reference serum sample and the neutralization titers were expressed relative to the titer for the reference sample in each assay. Analysis of sera from rabbits immunized with multiple doses of the rPA vaccine showed that for later bleeds, the quantitative agreement between the assays was good; however, for early bleeds, some heterogeneity in relative neutralization estimates was observed. Analysis of serum samples from rabbits, nonhuman primates, and humans immunized with the rPA vaccine showed that the relative neutralization estimates obtained in the different assays agreed to various extents, depending on the species of origin of the sera examined. We identified differences in the magnitudes of the Fc receptor-mediated neutralization associated with the J774A.1 cell- and RAW 264.7 cell-based assays, which may account for some of the species dependence of the assays. The differences in the relative neutralization estimates among the assays were relatively small and were always less than 2.5-fold. However, because toxin neutralization assays will likely be used to establish the efficacies of new anthrax vaccines, our findings should be considered when assay outputs are interpreted.
在非临床和临床研究中,已采用不同类型的炭疽毒素中和试验来测量炭疽疫苗引发的抗体水平。在本研究中,我们试图确定三种常用的毒素中和试验——基于J774A.1细胞、RAW 264.7细胞和CHO细胞的试验——对于接种由重组保护性抗原(rPA)组成的炭疽疫苗后获得的血清,是否能产生可比的中和活性估计值。为了比较这些试验,将血清与一个共同的参考血清样本一起进行检测,并且在每个试验中,中和滴度相对于参考样本的滴度来表示。对用多剂量rPA疫苗免疫的兔子的血清分析表明,对于后期采血,试验之间的定量一致性良好;然而,对于早期采血,观察到相对中和估计值存在一些异质性。对用rPA疫苗免疫的兔子、非人灵长类动物和人类的血清样本分析表明,在不同试验中获得的相对中和估计值在不同程度上是一致的,这取决于所检测血清的来源物种。我们发现基于J774A.1细胞和RAW 264.7细胞的试验在Fc受体介导的中和程度上存在差异,这可能是这些试验存在物种依赖性的部分原因。试验之间相对中和估计值的差异相对较小,且总是小于2.5倍。然而,由于毒素中和试验可能会用于确定新炭疽疫苗的效力,在解释试验结果时应考虑我们的发现。